A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
At a glance
Conditions
NCT03165734
Where you'd take part
This study runs at 207 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Aktobe Medical Center, Department of Hematology
Aktobe, Kazakhstanno site contact published
Alfred Hospital, Malignant Hematology and Stem Cell Transplantation Service
Melbourne, Victoria, Australiano site contact published
All India Institute of Medical Sciences
Dehradun, Uttarakhand, Indiano site contact published
American Oncology Partners of Maryland, PA
Bethesda, Marylandno site contact published
Andrzej Mielecki Independent Public Clinical Hospital of Medical University of Silesia in Katowice, Department of Hematology and Bone Marrow Transplantation
Katowice, Polandno site contact published
ASST Monza - Ospedale San Gerardo
Monza, Italyno site contact published
ASST Sette Laghi Hospital
Varese, Italyno site contact published
ASST Spedali Civili Brescia, Hematology Unit
Brescia, Italyno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Simran Singh · STUDY_DIRECTOR · Sobi, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Spleen volumeFrom baseline at 24 weeks
To compare the efficacy of pacritinib with that of physician's choice (P/C) therapy, as assessed by the proportion of patients achieving a ≥35% spleen volume reduction (SVR) as measured by magnetic resonance imaging (MRI, preferred) or computed tomography (CT) scans
- Total Symptom Score (TSS) (excluding tiredness)From baseline at Week 24
To compare the efficacy of pacritinib compared to P/C therapy, as assessed by the proportion of patients achieving a ≥50% reduction in Total Symptom Score (TSS). The TSS is the sum of the individual symptom scores for tiredness, early satiety, abdominal discomfort, night sweats, pruritus, bone pain, and pain under ribs on the left side. Symptoms are ranked 0 (absent) to 10 (worst imaginable)